Passive protection of purified yolk immunoglobulin administered against Shiga toxin 1 in mouse models

Canadian Journal of Microbiology

Volumn 56, Issue 12, 2010, Pages 1003-1010

  Wang, Qin ^a   Hou, Xiao Jun ^a   Cai, Kun ^a   Li, Tao ^a   Liu, Yue Nan ^a   Tu, Wei ^a   Xiao, Le ^a   Bao, Shi Zhong ^a   Shi, Jing ^a   Gao, Xiang ^a   Liu, Hao ^a   Tian, Ren Mao ^a   Wang, Hui ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Passive protection; Shiga toxin 1; Yolk immunoglobulin

Indexed keywords

BALB/C MICE; E. COLI SYSTEM; EGG YOLKS; ESCHERICHIA COLI O157:H7; HELA CELL; IN-VITRO; MOUSE MODELS; PASSIVE PROTECTION; PROTECTIVE EFFICACY; SHIGA TOXIN; THERAPEUTIC INTERVENTION; WIDE SPECTRUM; YOLK IMMUNOGLOBULIN;

AFFINITY CHROMATOGRAPHY; COLUMN CHROMATOGRAPHY; ESCHERICHIA COLI; PURIFICATION;

TOXIC MATERIALS;

IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN Y; NICKEL; VEROTOXIN 1;

ANTIBODY; CHROMATOGRAPHY; COLIFORM BACTERIUM; EGG; NICKEL; RODENT; TOXIN;

AFFINITY CHROMATOGRAPHY; ANTIBODY TITER; ARTICLE; BACTERIAL IMMUNITY; BAGG ALBINO MOUSE; CYTOKINE PRODUCTION; EGG YOLK; ESCHERICHIA COLI O157; HELA CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGLOBULIN PRODUCTION; IN VITRO STUDY; IN VIVO STUDY; INTOXICATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, NEUTRALIZING; ANTITOXINS; CHICKENS; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI O157; ESCHERICHIA COLI VACCINES; FEMALE; HELA CELLS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; IMMUNOGLOBULINS; MICE; MICE, INBRED BALB C; PROTEIN BINDING; RANDOM ALLOCATION; SHIGA TOXIN 1;

ESCHERICHIA COLI; MUS;

EID: 78650243309     PISSN: 00084166     EISSN: 14803275     Source Type: Journal    
DOI: 10.1139/W10-087     Document Type: Article

References (33)

1. Akita, E.M., and Nakai, S. 1993. Comparison of four purification methods for the production of immunoglobulins from eggs laid by hens immunized with an enterotoxigenic E. coli strain. J. Immunol. Methods, 160(2): 207-214. doi:10.1016/0022-1759(93)90179-B. PMID:8459107.
2. Bielaszewska, M., Clarke, I., Karmali, M.A., and Petric, M. 1997. Localization of intravenously administered verocytotoxins (Shiga-like toxins) 1 and 2 in rabbits immunized with homologous and heterologous toxoids and toxin subunits. Infect. Immun. 65(7): 2509-2516. PMID:9199412.
3. Calderwood, S.B., Auclair, F., Donohue-Rolfe, A., Keusch, G.T., and Mekalanos, J.J. 1987. Nucleotide sequence of the Shigalike toxin genes of Escherichia coli. Proc. Natl. Acad. Sci. U.S.A. 84(13): 4364-4368. doi:10.1073/pnas.84.13.4364. PMID:3299365.
4. Donohue-Rolfe, A., Jacewicz, M., and Keusch, G.T. 1989. Isolation and characterization of functional Shiga toxin subunits and renatured holotoxin. Mol. Microbiol. 3(9): 1231-1236. doi:10.1111/j.1365-2958.1989.tb00273.x. PMID:2677606.
5. Gao, X., Cai, K., Shi, J., Liu, H., Hou, X., Tu, W., et al. 2009. Immunogenicity of a novel Stx2B-Stx1B fusion protein in a mice model of Enterohemorrhagic Escherichia coli O157:H7 infection. Vaccine, 27(14): 2070-2076. doi:10.1016/j.vaccine.2009.01.115. PMID:19428832.
6. Girard, F., Batisson, I., Martinez, G., Breton, C., Harel, J., and Fairbrother, J.M. 2006. Use of virulence factor-specific egg yolk-derived immunoglobulins as a promising alternative to antibiotics for prevention of attaching and effacing Escherichia coli infections. FEMS Immunol. Med. Microbiol. 46(3): 340-350. doi:10.1111/j.1574-695X.2005.00030.x. PMID:16553806.
7. Inoue, K., Itoh, K., Nakao, H., Takeda, T., and Suzuki, T. 2004. Characterization of a Shiga toxin 1-neutralizing recombinant Fab fragment isolated by phage display system. Tohoku J. Exp. Med. 203(4): 295-303. doi:10.1620/tjem.203.295. PMID:15297734.
8. Jackson, M.P., Newland, J.W., Holmes, P.K., and O'Brien, A.D. 1987. Nucleotide sequence analysis of the structural genes for Shiga-like toxin I encoded by bacteriophage 933J from Escherichia coli. Microb. Pathog. 2(2): 147-153. doi:10.1016/0882-4010(87)90106-9.
9. Karch, H., Tarr, P.I., and Bielaszewska, M. 2005. Enterohaemorrhagic Escherichia coli in human medicine. Int. J. Med. Microbiol. 295(6-7): 405-418. doi:10.1016/j.ijmm.2005.06.009.PMID:16238016.
10. Karmali, M.A. 1989. Infection by verocytotoxin-producing Escherichia coli. Clin. Microbiol. Rev. 2(1): 15-38. PMID:2644022.
11. Karmali, M.A., Petric, M., Lim, C., Fleming, P.C., Arbus, G.S., and Lior, H. 1985. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J. Infect. Dis. 151(5): 775-782. PMID:3886804.
12. Kitov, P.I., Sadowska, J.M., Mulvey, G., Armstrong, G.D., Ling, H., Pannu, N.S., et al. 2000. Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands. Nature, 403(6770): 669-672. doi:10.1038/35001095. PMID:10688205.
13. Kovacs-Nolan, J., and Mine, Y. 2004. Avian egg antibodies: basic and potential applications. Avian Poult. Biol. Rev. 15(1): 25-46. doi:10.3184/147020604783637462.
14. Kühlmann, R., Wiedemann, V., Schmidt, P., Wanke, R., Linckh, E., and Lösch, U. 1988. Chicken egg antibodies for prophylaxis and therapy of infectious intestinal diseases. I. Immunization and antibody determination. Zentbl. Vetmed. Reihe B. 35(8): 610-616. PMID:3057771.
15. Leslie, G.A., and Clem, L.W. 1969. Phylogeny of immunoglobulin structure and function. III. Immunoglobulins of the chicken. J. Exp. Med. 130(6): 1337-1352. doi:10.1084/jem.130.6.1337. PMID:5352783.
16. Malik, M.W., Ayub, N., and Qureshi, I.Z. 2006. Passive immunization using purified IgYs against infectious bursal disease of chickens in Pakistan. J. Vet. Sci. 7(1): 43-46. PMID:16434848.
17. Mukherjee, J., Chios, K., Fishwild, D., Hudson, D., O'Donnell, S., Rich, S.M., et al. 2002. Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection. Infect. Immun. 70(2): 612-619. doi:10.1128/IAI.70.2.612-619.2002. PMID:11796590.
18. Mulvey, G.L., Marcato, P., Kitov, P.I., Sadowska, J., Bundle, D.R., and Armstrong, G.D. 2003. Assessment in mice of the therapeutic potential of tailored, multivalent Shiga toxin carbohydrate ligands. J. Infect. Dis. 187(4): 640-649. doi:10.1086/373996. PMID:12599081.
19. Nakao, H., Kataoka, C., Kiyokawa, N., Fujimoto, J., Yamasaki, S., and Takeda, T. 2002. Monoclonal antibody to Shiga toxin 1, which blocks receptor binding and neutralizes cytotoxicity. Microbiol. Immunol. 46(11): 777-780. PMID:12516775.
20. Nataro, J.P., and Kaper, J.B. 1998. Diarrheagenic Escherichia coli. Clin. Microbiol. Rev. 11(1): 142-201. PMID:9457432.
21. Natori, Y. 2002. New drugs that prevent cytotoxicity of Shiga toxins. Nippon Rinsho, 60(6): 1131-1137. PMID:12078085.
22. Nishikawa, K., Matsuoka, K., Kita, E., Okabe, N., Mizuguchi, M., Hino, K., et al. 2002. A therapeutic agent with oriented carbohydrates for treatment of infections by Shiga toxin-producing Escherichia coli O157:H7. Proc. Natl. Acad. Sci. U.S.A. 99(11): 7669-7674. doi:10.1073/pnas.112058999. PMID:12032341.
23. Paton, A.W., Morona, R., and Paton, J.C. 2000. A new biological agent for treatment of Shiga toxigenic Escherichia coli infections and dysentery in humans. Nat. Med. 6(3): 265-270. doi:10.1038/73111. PMID:10700227.
24. Reed, J., and Muench, H. 1938. A simple method for estimating fifty percent endpoints. Am. J. Hyg. 27: 493-497.
25. Sarker, S.A., Casswall, T.H., Juneja, L.R., Hoq, E., Hossain, I., Fuchs, G.J., and Hammarström, L. 2001. Randomized, placebocontrolled, clinical trial of hyperimmunized chicken egg yolk immunoglobulin in children with rotavirus diarrhea. J. Pediatr. Gastroenterol. Nutr. 32(1): 19-25. doi:10.1097/00005176-200101000-00009. PMID:11176319.
26. Schade, R., Calzado, E.G., Sarmiento, R., Chacana, P.A., Porankiewicz-Asplund, J., and Terzolo, H.R. 2005. Chicken egg yolk antibodies (IgY-technology): a review of progress in production and use in research and human and veterinary medicine. Altern. Lab. Anim. 33(2): 129-154. PMID:16180988.
27. Slutsker, L., Ries, A.A., Maloney, K., Wells, J.G., Greene, K.D., and Griffin, P.M. 1998. A nationwide case-control study of Escherichia coli O157:H7 infection in the United States. J. Infect. Dis. 177(4): 962-966. PMID:9534969.
28. Smith, M.J., Carvalho, H.M., Melton-Celsa, A.R., and O'Brien, A.D. 2006. The 13C4 monoclonal antibody that neutralizes Shiga toxin Type 1 (Stx1) recognizes three regions on the Stx1 B subunit and prevents Stx1 from binding to its eukaryotic receptor globotriaosylceramide. Infect. Immun. 74(12): 6992-6998. doi:10.1128/IAI.01247-06. PMID:17030576.
29. Takao, T., Tanabe, T., Hong, Y.M., et al. 1988. Identity of molecular structure of Shiga-like toxin I (VT1) from Escherichia coli O157:H7 with that of Shiga toxin. Microb. Pathog. 5(5): 357-369. doi:10.1016/0882-4010(88)90036-8.
30. Tzipori, S., Sheoran, A., Akiyoshi, D., Donohue-Rolfe, A., and Trachtman, H. 2004. Antibody therapy in the management of Shiga toxin-induced hemolytic uremic syndrome. Clin. Microbiol. Rev. 17(4): 926-941. doi:10.1128/CMR.17.4.926-941. 2004. PMID:15489355.
31. Van Nguyen, S., Umeda, K., Yokoyama, H., Tohya, Y., and Kodama, Y. 2006. Passive protection of dogs against clinical disease due to Canine parvovirus-2 by specific antibody from chicken egg yolk. Can. J. Vet. Res. 70(1): 62-64. PMID: 16548334.
32. Yamagami, S., Motoki, M., Kimura, T., Izumi, H., Takeda, T., Katsuura, Y., and Matsumoto, Y. 2001. Efficacy of postinfection treatment with anti-Shiga toxin (Stx) 2 humanized monoclonal antibody TMA-15 in mice lethally challenged with Stxproducing Escherichia coli. J. Infect. Dis. 184(6): 738-742. doi:10.1086/323082. PMID:11517435.
33. Williams, J. 1962. Serum proteins and the livetins of hen's-egg yolk. Biochem. J. 83(2): 346-355. PMID:14040270.